COVID19 (disease)
FDA Commissioner Makary Addresses COVID-19 Vaccine Safety Concerns Amid Internal Debates and Investigations
Marty Makary; FDA; COVID-19 vaccine; myocarditis; vaccine deaths; safety warnings; RFK Jr.; mRNA vaccines
CDC highlights strong effectiveness of 2024–2025 COVID-19 shots in kids while FDA reviews reports of alleged post-vaccination deaths
CDC; FDA; COVID-19 vaccine; children; pediatrics; vaccine effectiveness; emergency department visits; urgent care visits; safety review; alleged deaths; VAERS
FDA Broadens COVID-19 Vaccine Safety Probe to Adults Under New Health Leadership
FDA; COVID-19 vaccines; safety review; adults; Robert F. Kennedy Jr.; vaccine deaths; public trust; Pfizer; Moderna; myocarditis
FDA names Tracy Beth Heg as acting CDER chief
Tracy Beth Heg; acting CDER chief; FDA leadership; Center for Drug Evaluation and Research; COVID-19 vaccine safety; drug regulation; U.S. Food and Drug Administration
Former FDA Chiefs Criticize Proposed Vaccine Policy Changes at ACIP Meeting
former FDA commissioners; CDC; ACIP meeting; vaccine policy changes; COVID-19 vaccines; Vinay Prasad; Center for Biologics Evaluation and Research; vaccine safety regulation; Senator Bill Cassidy; New England Journal of Medicine commentary
FDA Refuses to Release Detailed Data on Claimed COVID Vaccine-Linked Child Deaths in Near Term
FDA; COVID-19 vaccine; child deaths; myocarditis; vaccine safety; Vinay Prasad; data release; vaccine oversight
Recent Developments on Vinay Prasad’s Leaked FDA Memo, Alzheimer’s Disease Updates, and Next-Gen Obesity Drugs
Vinay Prasad FDA memo; COVID-19 vaccine deaths children; FDA vaccine approval changes; Alzheimer’s disease research 2025; obesity drugs next generation; COVID-19 vaccine safety controversy; FDA vaccine policy overhaul
FDA’s Vinay Prasad Links 10 Child Deaths to COVID-19 Vaccines, Calls for Stricter Review Guidelines
FDA; Vinay Prasad; COVID-19 vaccines; child deaths; myocarditis; vaccine safety; vaccine regulation; biologics evaluation; VAERS; stricter vaccine guidelines
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx PCR Platform to Support Submission to the U.S. FDA
Co-Diagnostics; clinical evaluations; multiplex test; point-of-care; Co-Dx PCR Platform; FDA 510(k); Flu A/B; COVID-19; RSV; regulatory submission
Pfizer Cuts 11 R&D Programs amid Ongoing Revenue Declines and Cost Realignment Efforts
Pfizer; R&D cuts; revenue decline; cost savings; Q3 2025 earnings; COVID-19 product sales; digital enablement; AI in R&D; Seagen acquisition